Zepbound vs Wegovy: Two Weight-Management GLP-1s Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

You are reading part of the PlexusDx Education Hub, covering GLP-1 therapies, weight-management protocols, and the genetic variables behind every metabolic decision. Browse all Peptides & GLP-1 education

This is independent editorial analysis. PlexusDx has no commercial relationship with Novo Nordisk, Eli Lilly, or any brand mentioned below.

Of all the GLP-1 comparisons people search for, Zepbound versus Wegovy is the one where both drugs actually share the same headline job: chronic weight management. Wegovy is semaglutide from Novo Nordisk; Zepbound is tirzepatide from Eli Lilly. Because their indications overlap so closely, the interesting differences are mechanical, evidential, and financial. Here is how the two compare, followed by the genetic groundwork that sits beneath either regimen.

Two drugs cleared for the same job

Unlike most pairings in this class, Wegovy and Zepbound both hold a chronic weight-management indication. Wegovy (semaglutide 2.4 mg) earned it in 2021; Zepbound (tirzepatide) in 2023, with an added obstructive sleep apnea clearance in 2024 under SURMOUNT-OSA. That overlap is why the two are so often weighed against each other rather than against the diabetes-first brands.

Single versus dual incretin action

The mechanistic split is straightforward: semaglutide is GLP-1-selective, acting on one incretin receptor, while tirzepatide is a GIP/GLP-1 dual agonist acting on two. Dulaglutide and liraglutide are also GLP-1-selective; retatrutide, a triple GLP-1/GIP/glucagon agonist, is investigational and not FDA-approved as of April 2026. All of them, single- or dual-target, work through the GLP-1 receptor to slow gastric emptying, flatten post-meal glucose, and boost satiety.

Indications and the sleep-apnea distinction

Both brands treat obesity, but their labels are not identical. The wider class sorts this way: Wegovy (semaglutide 2.4 mg) for weight management in 2021; Zepbound (tirzepatide) for weight management in 2023 and sleep apnea in 2024; Ozempic (semaglutide) for diabetes in 2017; Rybelsus (oral semaglutide) for diabetes in 2019; Mounjaro (tirzepatide) for diabetes in 2022; Trulicity (dulaglutide) for diabetes in 2014; Victoza (liraglutide) for diabetes in 2010. The SURMOUNT-OSA clearance is unique to Zepbound in this pair. Retatrutide is investigational.

What the head-to-head and program trials show

This pairing has more direct evidence than most. Semaglutide's weight-management data comes from the STEP program, with SUSTAIN and SELECT covering diabetes and cardiovascular outcomes; tirzepatide's comes from SURMOUNT and SURPASS. Critically, SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes and reported larger mean weight reduction with tirzepatide in that specific trial. Weight-management studies used different endpoints, so even here the read is trial-by-trial rather than a blanket ruling.

Side effects across both regimens

Tolerability tracks the class. Both carry the boxed warning for thyroid C-cell tumors seen in rodent studies and are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal symptoms lead the common side effects and are usually worst during escalation. Pancreatitis, gallbladder events, and acute kidney injury tied to dehydration are uncommon but serious enough to warrant provider oversight.

Pricing and the compounded pathway

As of April 2026, published U.S. list prices for FDA-approved brands in this category ranged from roughly $815 to $1,620 per month (manufacturer list pricing). Actual out-of-pocket cost depends on insurance, the indication on the prescription, savings-card eligibility, and whether a licensed compounding pathway applies. Because both Wegovy and Zepbound share the weight-management indication, coverage disputes between them are common.

The genetics beneath either choice

The molecule may differ, but the inherited setup does not. FTO variants influence appetite and adiposity set-point; GLP1R encodes the receptor both semaglutide and tirzepatide engage; MC4R anchors energy balance; and TCF7L2 links to glucose control and GLP-1 secretion. These are pathway-level markers: they will not tell you whether Wegovy or Zepbound performs better for you, but they describe the biology any GLP-1 regimen has to operate within.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The differentiator is the upstream genetic context: before starting any protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including the FTO, GLP1R, MC4R, and TCF7L2 variants shaping your baseline appetite and energy-balance biology. Pairing that profile with the protocol is the test before you invest approach.

Related reading on PlexusDx: Wegovy Cost, Wegovy for Weight Loss, Wegovy Price, What is Wegovy.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and does not sell, prescribe, or recommend other GLP-1-category peptides beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

Are Wegovy and Zepbound both approved for weight loss?

Yes. Both hold FDA clearance for chronic weight management, Wegovy (semaglutide 2.4 mg) since 2021 and Zepbound (tirzepatide) since 2023. Zepbound additionally carries a 2024 obstructive sleep apnea indication. That shared weight-management label is what makes this the most direct comparison in the GLP-1 category.

Did a trial compare them directly?

Partly. SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes and showed greater mean weight reduction with tirzepatide in that trial. However, the dedicated weight-management programs, STEP for semaglutide and SURMOUNT for tirzepatide, used different endpoints, so results should be read study by study.

Will the genetic test tell me which one to pick?

No. The Precision Peptide Genetic Test does not predict response to Wegovy, Zepbound, or any drug, and it is not pharmacogenomic. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that outline baseline appetite and energy-balance biology, context for your provider conversation rather than a prescription.

What makes this pair different from other GLP-1 comparisons?

Both drugs share the chronic weight-management indication, which few other pairings do. That overlap shifts the comparison away from which is approved for weight loss toward mechanism, trial endpoints, tolerability, and cost, plus the genetic groundwork that applies regardless of which molecule a provider recommends.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.